Analysts Expect Eli Lilly and Company (NYSE:LLY) Will Post Earnings of $2.24 Per Share

Brokerages expect Eli Lilly and Company (NYSE:LLYGet Rating) to announce earnings of $2.24 per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Eli Lilly and’s earnings, with estimates ranging from $1.90 to $2.40. Eli Lilly and reported earnings per share of $1.87 in the same quarter last year, which would indicate a positive year over year growth rate of 19.8%. The business is expected to report its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Eli Lilly and will report full year earnings of $8.75 per share for the current financial year, with EPS estimates ranging from $8.53 to $9.13. For the next fiscal year, analysts expect that the business will post earnings of $9.90 per share, with EPS estimates ranging from $9.00 to $10.41. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, February 3rd. The company reported $2.49 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.51 by ($0.02). Eli Lilly and had a return on equity of 96.36% and a net margin of 19.71%. The firm had revenue of $8 billion during the quarter, compared to the consensus estimate of $7.89 billion. During the same period last year, the firm posted $2.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year.

Several equities research analysts have weighed in on the company. Mizuho reduced their price objective on Eli Lilly and from $302.00 to $293.00 and set a “buy” rating on the stock in a research note on Friday, February 4th. Barclays boosted their price objective on Eli Lilly and from $280.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, December 20th. Berenberg Bank upped their target price on Eli Lilly and from $270.00 to $305.00 and gave the company a “buy” rating in a research note on Monday, December 20th. Bank of America raised their price target on Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Finally, Daiwa Capital Markets started coverage on Eli Lilly and in a research report on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $297.39.

NYSE LLY traded down $0.81 during trading hours on Friday, hitting $301.86. 1,898,106 shares of the company were exchanged, compared to its average volume of 2,995,721. The stock has a 50-day moving average price of $271.34 and a 200 day moving average price of $258.85. The company has a quick ratio of 0.97, a current ratio of 1.23 and a debt-to-equity ratio of 1.68. Eli Lilly and has a 52 week low of $178.58 and a 52 week high of $314.00. The stock has a market cap of $287.48 billion, a PE ratio of 49.16, a price-to-earnings-growth ratio of 2.44 and a beta of 0.43.

In related news, major shareholder Lilly Endowment Inc sold 139,045 shares of the firm’s stock in a transaction dated Friday, April 8th. The stock was sold at an average price of $310.79, for a total transaction of $43,213,795.55. Following the sale, the insider now owns 105,573,810 shares of the company’s stock, valued at $32,811,284,409.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Marschall S. Runge acquired 202 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The shares were bought at an average cost of $246.78 per share, for a total transaction of $49,849.56. The disclosure for this purchase can be found here. Insiders have sold a total of 1,088,551 shares of company stock worth $307,943,730 in the last three months. Corporate insiders own 0.12% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Annex Advisory Services LLC boosted its position in Eli Lilly and by 3.5% during the first quarter. Annex Advisory Services LLC now owns 2,403 shares of the company’s stock valued at $688,000 after purchasing an additional 82 shares in the last quarter. IFM Investors Pty Ltd raised its stake in shares of Eli Lilly and by 19.0% in the first quarter. IFM Investors Pty Ltd now owns 128,773 shares of the company’s stock worth $36,877,000 after purchasing an additional 20,566 shares during the last quarter. Wealthcare Advisory Partners LLC raised its stake in shares of Eli Lilly and by 8.8% in the first quarter. Wealthcare Advisory Partners LLC now owns 3,074 shares of the company’s stock worth $880,000 after purchasing an additional 249 shares during the last quarter. CRA Financial Services LLC grew its holdings in Eli Lilly and by 1.0% during the first quarter. CRA Financial Services LLC now owns 4,374 shares of the company’s stock worth $1,253,000 after acquiring an additional 45 shares during the period. Finally, G&S Capital LLC grew its holdings in Eli Lilly and by 2.0% during the first quarter. G&S Capital LLC now owns 11,673 shares of the company’s stock worth $3,343,000 after acquiring an additional 229 shares during the period. 82.16% of the stock is currently owned by institutional investors.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.